Clinical trial / 2021
Co-administering piperine at 5 mg or 25 mg with resveratrol did not significantly alter resveratrol pharmacokinetics in healthy volunteers.
In a randomized, double-blind, three-arm pilot study, 24 healthy participants were assigned to a single dose of 2.5 g resveratrol combined with 0 mg, 5 mg, or 25 mg of piperine. Serum levels were analyzed through 24 hours post-dose, and adverse events were monitored for 30 days. Pharmacokinetic values for resveratrol showed Cmax of 18.5 ± 16 ng/mL for resveratrol alone, 29 ± 29 ng/mL with 5 mg piperine, and 16 ± 13 ng/mL with 25 mg piperine, with no significant relationship between dose and pharmacokinetic values. All subjects tolerated the therapy with minimal to no toxicity.
- Study type
- Randomized, double-blind, three-arm pilot trial
- Who was studied
- 24 healthy volunteers
- What was measured
- Single-dose pharmacokinetics of resveratrol and resveratrol-glucuronide, and associated toxicities
THE PAPER
A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol.
Bailey HH, Johnson JJ, Lozar T, Scarlett CO, Wollmer BW, Kim K, Havinghurst T, Ahmad N. Eur J Cancer Prev, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.